on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Expands Revenue Streams with New Manufacturing Agreement
Zomedica Corp., a notable player in animal health, has signed a contract manufacturing and services agreement with Rahm Sensor Development. This venture introduces Zomedica to the manufacturing of Rahm’s Cell-Guardian™, a device aimed at enhancing safety in high-risk settings like institutional environments. Engineering services and customer support will also be provided by Zomedica.
This partnership is crafted to diversify Zomedica’s revenue streams, reducing dependency on animal health. The agreement is expected to favor Zomedica by generating additional contract-based revenue, optimizing asset usage, and maintaining manageable fixed costs as laid out by CEO Larry Heaton.
The wearable technology market, poised to see significant growth, aligns with Zomedica's diversification strategy. By leveraging existing infrastructure, Zomedica aims to strengthen its market position as a diversified medical technology entity, while keeping the focus on its core operations.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news